BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'

Reuters

Dec 17, 2024

BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'

** Shares of medical device maker Zimmer Biomet ZBH.N up 1.3% at 108.25 premarket

** Brokerage J.P.Morgan upgrades stock to "overweight" from "neutral"; raises PT to $128 from $125

** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters

** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market

** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance

** 11 of 31 brokerages rate the stock "buy" or higher, 18 "hold" and two "sell"; with a median PT of $122.50

** Up to Monday's close, stock has fallen ~12% YTD

(Reporting by Neil J Kanatt in Bengaluru)

((Neil.JKanatt@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492548939"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492548939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492548939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492548939","market":"us","top_or_hot":-1,"title":"BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'</title></head><body><p>** Shares of medical device maker Zimmer Biomet <span>ZBH.N</span> up 1.3% at 108.25 premarket</p><p>** Brokerage J.P.Morgan upgrades stock to \"overweight\" from \"neutral\"; raises PT to $128 from $125</p><p>** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters </p><p>** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market</p><p>** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance</p><p>** 11 of 31 brokerages rate the stock \"buy\" or higher, 18 \"hold\" and two \"sell\"; with a median PT of $122.50</p><p>** Up to Monday's close, stock has fallen ~12% YTD</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p> ((Neil.JKanatt@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-17 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'</title></head><body><p>** Shares of medical device maker Zimmer Biomet <span>ZBH.N</span> up 1.3% at 108.25 premarket</p><p>** Brokerage J.P.Morgan upgrades stock to \"overweight\" from \"neutral\"; raises PT to $128 from $125</p><p>** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters </p><p>** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market</p><p>** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance</p><p>** 11 of 31 brokerages rate the stock \"buy\" or higher, 18 \"hold\" and two \"sell\"; with a median PT of $122.50</p><p>** Up to Monday's close, stock has fallen ~12% YTD</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p> ((Neil.JKanatt@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBH","symbol_name":"齐默巴奥米特控股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nL4N3NI0WC:1","article_id":"2492548939","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492548939","pubTimestamp":1734440467,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'** Shares of medical device maker Zimmer Biomet ZBH.N up 1.3% at 108.25 premarket** Brokerage J.P.Morgan upgrades stock to \"overweight\" from \"neutral\"; raises PT to $128 from $125** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters ** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance** 11 of 31 brokerages rate the stock \"buy\" or higher, 18 \"hold\" and two \"sell\"; with a median PT of $122.50** Up to Monday's close, stock has fallen ~12% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ZBH":"齐默巴奥米特控股"},"translate_title":"摩根大通将股票评级上调至“增持”后，Zimmer Biomet股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":0.9},"content_text":"BUZZ-Zimmer Biomet up after J.P.Morgan upgrades stock to 'overweight'** Shares of medical device maker Zimmer Biomet ZBH.N up 1.3% at 108.25 premarket** Brokerage J.P.Morgan upgrades stock to \"overweight\" from \"neutral\"; raises PT to $128 from $125** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters ** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance** 11 of 31 brokerages rate the stock \"buy\" or higher, 18 \"hold\" and two \"sell\"; with a median PT of $122.50** Up to Monday's close, stock has fallen ~12% YTD (Reporting by Neil J Kanatt in Bengaluru) ((Neil.JKanatt@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}